Premium
P3‐320: INCREASED PLASMA TRIMETHYLAMINE‐ N ‐OXIDE (TMAO) IS ASSOCIATED WITH LOWER HIPPOCAMPAL BLOOD FLOW
Author(s) -
Beilfuss Matthew A.,
Vogt Nicholas M.,
Romano Kymberleigh,
Oh Jennifer M.,
Amador-Noguez Daniel,
Johnson Sterling C.,
Asthana Sanjay,
Rey Federico E.,
Bendlin Barbara B.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1681
Subject(s) - trimethylamine n oxide , cerebral blood flow , white matter , medicine , hippocampal formation , lesion , metabolite , dementia , endocrinology , physiology , cardiology , pathology , chemistry , magnetic resonance imaging , trimethylamine , disease , biochemistry , radiology
were associatedwith driving performance and driving decline among cognitively normal older adults. Methods: Participants, 65 years of age or older, were enrolled from longitudinal studies at the Knight Alzheimer’s Disease Research Center at Washington University. Cox proportional hazards models evaluated whether a depression diagnosis, depressive symptoms (Geriatric Depression Scale [GDS]), antidepressant use, CSF biomarkers (}$^[fish 0,mfnt]>bamyloid42 [A}$^[fish 0,mfnt]>b42], tau, and phosphorylated tau181 [ptau181]), and amyloid imaging (Pittsburgh Compound B and Florbetapir) were associated with time to receiving a rating of marginal/ fail on the driving test. Interactions among the variables were tested. Age was adjusted in all models. Results:Data were available from 141 participants with ages ranging from 65.4 to 88.2 years with a mean follow up of 2.4 years. A depression diagnosis (p1⁄4.027) was associated with a faster time to receiving a marginal/fail rating on a road test while adjusting for age, and antidepressant use. Depression and all CSF and imaging AD biomarkers (p<.05) were associated with poor driving performance on the road test. In the model with CSF tau, both depression (p1⁄4.024) and antidepressant use (p1⁄4.019) usewere statistically significant predictors. However, there were no interaction effects between depression, antidepressant use and biomarker groups on driving performance. Depressive symptoms (GDS) were not a significant predictor of driving performance. Participants with depression and preclinical AD were faster to receive a marginal/fail rating on the road test compared to participants with no depression or abnormal biomarkers. Conclusions: While, as previously shown, preclinical AD alone predicts a faster time to receiving a marginal/fail rating, these results suggest that also having a diagnosis of depression accelerates the onset of driving problems in cognitively normal older adults (see Figure 1).